Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present NewLink Genetics Corp (NASDAQ: NLNK).

Full DD Report for NLNK

You must become a subscriber to view this report.


Recent News from (NASDAQ: NLNK)

NewLink Genetics Presents Encouraging Updated Phase 1 Data with Indoximod Plus Chemotherapy in Frontline AML in an Oral Session at 2018 ASH Annual Meeting
Updated Phase 1 data for indoximod plus standard-of-care chemotherapy in newly diagnosed AML show post-induction minimal residual disease (MRD) negativity rate of 86% and post-consolidation MRD negativity of 100% Safety data from this study indicate the combination treatment regimen...
Source: Business Wire
Date: December, 02 2018 12:30
NewLink Genetics Announces Publication of Abstracts for Presentation at the Society for Immunotherapy for Cancer (SITC) Conference
AMES, Iowa, Nov. 06, 2018 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that the following abstracts have been published and are now available on the Society for Immunotherapy of Cancer (SITC) Conference 2018 website. Abstracts for poster present...
Source: GlobeNewswire
Date: November, 06 2018 09:00
Analysis: Positioning to Benefit within Mercury, Lincoln Electric, Sprint, Fred's, NewLink Genetics, and El Paso Electric - Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, Nov. 06, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Mercury Systems Inc (NASDAQ:MRCY), Lincoln Electric Holdings, Inc. (NASDA...
Source: GlobeNewswire
Date: November, 06 2018 07:25
CORRECTED: NewLink Genetics Reports Third Quarter 2018 Financial Results and Announces Abstracts to Be Presented at Upcoming Medical Meetings
AMES, Iowa, Nov. 02, 2018 (GLOBE NEWSWIRE) -- In a release issued under the same headline yesterday by NewLink Genetics Corporation (NASDAQ:NLNK), the balance statement included in the press release was incorrect. The corrected release follows: NewLink Genetics Corporation (NASDAQ:NLN...
Source: GlobeNewswire
Date: November, 02 2018 17:05
NewLink Genetics Corp (NLNK) CEO Charles Link on Q3 2018 Results - Earnings Call Transcript
NewLink Genetics Corp (NLNK) Q3 2018 Earnings Conference Call November 1, 2018, 16:30 ET Executives Lisa Miller - Director, IR Charles Link - Co-Founder, Chairman, CEO & Chief Scientific Officer Eugene Kennedy - Chief Medical Officer Carl Langren - CFO & Principal Accou...
Source: SeekingAlpha
Date: November, 01 2018 18:52
NewLink Genetics beats by $0.20, misses on revenue
NewLink Genetics (NASDAQ: NLNK ): Q3 GAAP EPS of -$0.20 beats by $0.20 . Revenue of $0.12M (-97.8% Y/Y) misses by $2.05M . Press Release More news on: NewLink Genetics Corporation, Earnings news and commentary, Healthcare stocks news, ,
Source: SeekingAlpha
Date: November, 01 2018 16:03
NewLink Genetics Reports Third Quarter 2018 Financial Results and Announces Abstracts to Be Presented at Upcoming Medical Meetings
AMES, Iowa, Nov. 01, 2018 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today reported consolidated financial results for the third quarter 2018 and reviewed recent highlights and upcoming milestones. “NewLink Genetics continues to produce encouraging data sup...
Source: GlobeNewswire
Date: November, 01 2018 16:01
NewLink Genetics Announces Oral Presentation at the 2018 American Society of Hematology (ASH) Annual Meeting
AMES, Iowa, Nov. 01, 2018 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) announced today that an abstract with data pertaining to the use of the Company's investigational immuno-oncology molecule, indoximod, in combination therapy for patients with newly diagnosed acute ...
Source: GlobeNewswire
Date: November, 01 2018 10:00
NewLink Genetics to Participate in the Stifel 2018 Healthcare Conference
AMES, Iowa, Oct. 30, 2018 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), a clinical stage biopharmaceutical company focused on developing novel immuno-oncology therapeutic candidates, announced today it will present at the Stifel 2018 Healthcare Conference. The conferen...
Source: GlobeNewswire
Date: October, 30 2018 09:00
NewLink Genetics to Host Its Third Quarter 2018 Financial Results Conference Call on November 1, 2018
AMES, Iowa, Oct. 18, 2018 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that it will release its third quarter 2018 financial results on Thursday, November 1, 2018. The company has scheduled a conference call for 4:30 PM ET the same day to d...
Source: GlobeNewswire
Date: October, 18 2018 16:01

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-141.721.751.791.71240,802
2018-12-131.801.721.811.70437,475
2018-12-121.741.801.841.73290,456
2018-12-111.811.731.841.72202,035
2018-12-101.821.791.841.735449,933

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1441,15962,65865.6883Short
2018-12-1354,652179,33330.4751Cover
2018-12-1239,04789,47343.6411Short
2018-12-1135,37458,65760.3065Short
2018-12-1058,249144,69040.2578Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on NLNK.


About NewLink Genetics Corp (NASDAQ: NLNK)

Logo for NewLink Genetics Corp (NASDAQ: NLNK)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: NLNK)

      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 16 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 15 2018
      Statement of beneficial ownership of common stock by certain persons
      Filing Type: SC 13GFiling Source: edgar
      Filing Date: May, 10 2018
      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 09 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 03 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 01 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: April, 25 2018
      Filing Type: CT ORDERFiling Source: edgar
      Filing Date: April, 19 2018
      Filing Type: CT ORDERFiling Source: edgar
      Filing Date: April, 19 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: April, 17 2018

       

       


      Daily Technical Chart for (NASDAQ: NLNK)

      Daily Technical Chart for (NASDAQ: NLNK)


      Stay tuned for daily updates and more on (NASDAQ: NLNK)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: NLNK)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in NLNK is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of NLNK and does not buy, sell, or trade any shares of NLNK. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/